| A landscape of driver mutations in melanoma E Hodis, IR Watson, GV Kryukov, ST Arold, M Imielinski, JP Theurillat, ... Cell 150 (2), 251-263, 2012 | 3040 | 2012 |
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling N Wagle, C Emery, MF Berger, MJ Davis, A Sawyer, P Pochanard, ... Journal of clinical oncology 29 (22), 3085-3096, 2011 | 1215 | 2011 |
| Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... Annals of Oncology 31 (11), 1491-1505, 2020 | 1029 | 2020 |
| The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma EM Van Allen, N Wagle, A Sucker, DJ Treacy, CM Johannessen, ... Cancer discovery 4 (1), 94-109, 2014 | 975 | 2014 |
| Melanoma genome sequencing reveals frequent PREX2 mutations MF Berger, E Hodis, TP Heffernan, YL Deribe, MS Lawrence, ... Nature 485 (7399), 502-506, 2012 | 902 | 2012 |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 877 | 2017 |
| High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing N Wagle, MF Berger, MJ Davis, B Blumenstiel, M DeFelice, P Pochanard, ... Cancer discovery 2 (1), 82-93, 2012 | 650 | 2012 |
| Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ... Cancer discovery 4 (10), 1140-1153, 2014 | 617 | 2014 |
| Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine EM Van Allen, N Wagle, P Stojanov, DL Perrin, K Cibulskis, S Marlow, ... Nature medicine 20 (6), 682-688, 2014 | 575 | 2014 |
| MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition N Wagle, EM Van Allen, DJ Treacy, DT Frederick, ZA Cooper, ... Cancer discovery 4 (1), 61-68, 2014 | 535 | 2014 |
| A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors M Slyper, CBM Porter, O Ashenberg, J Waldman, E Drokhlyansky, ... Nature medicine 26 (5), 792-802, 2020 | 525 | 2020 |
| A p53-dependent checkpoint pathway prevents rereplication C Vaziri, S Saxena, Y Jeon, C Lee, K Murata, Y Machida, N Wagle, ... Molecular cell 11 (4), 997-1008, 2003 | 485 | 2003 |
| Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma JA Perry, A Kiezun, P Tonzi, EM Van Allen, SL Carter, SC Baca, ... Proceedings of the National Academy of Sciences 111 (51), E5564-E5573, 2014 | 453 | 2014 |
| A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition SR Whittaker, JP Theurillat, E Van Allen, N Wagle, J Hsiao, GS Cowley, ... Cancer discovery 3 (3), 350-362, 2013 | 442 | 2013 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 441 | 2020 |
| A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma JE Rosenberg, RM Bambury, EM Van Allen, HA Drabkin, PN Lara, ... Investigational new drugs 32, 178-187, 2014 | 404 | 2014 |
| Response and acquired resistance to everolimus in anaplastic thyroid cancer N Wagle, BC Grabiner, EM Van Allen, A Amin-Mansour, A Taylor-Weiner, ... New England Journal of Medicine 371 (15), 1426-1433, 2014 | 369 | 2014 |
| Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine AJ Aguirre, JA Nowak, ND Camarda, RA Moffitt, AA Ghazani, ... Cancer discovery 8 (9), 1096-1111, 2018 | 333 | 2018 |
| Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems S Alon, DR Goodwin, A Sinha, AT Wassie, F Chen, ER Daugharthy, ... Science 371 (6528), eaax2656, 2021 | 332 | 2021 |
| Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations LG Ahronian, EM Sennott, EM Van Allen, N Wagle, EL Kwak, JE Faris, ... Cancer discovery 5 (4), 358-367, 2015 | 330 | 2015 |
